Identification of Transcriptional Level Variations in MicroRNA-221 and MicroRNA-222 As Alternate Players in the Thyroid Cancer Tumor Microenvironment

Overview

Journal Sci Rep

Specialty Science

Date 2023 Sep 22

PMID 37737255

Authors

Rashida Khan

Aayesha Riaz

Samina Asghar Abbasi

Tanzeela Sadaf

Ruqia Mehmood Baig

Qaisar Mansoor

Affiliations

Soon will be listed here.

Abstract

Thyroid cancer (TC) is caused by genetic factors and or their cross talk with lifestyle and environment. An important role of miRNA involvement has been identified in different human diseases alongside the cancer. The growing cloud of miRNA discoveries narrates miRNA-221 and miRNA-222 as key elements of ready arsenal in the cancer micro-niches. The aim of present study was to identify the variations of miRNA-221 and miRNA-222 expression in TC tissues and their likely association with TC. miRNA-221 and miRNA-222 were investigated for their expressional alterations in TC tissue samples and healthy thyroid tissue. Expression of miRNA-221 and -222 was analyzed through real time PCR. The relative gene expression of both the miRNA was quantified and statistically evaluated. miRNA-221 and miRNA-222 were found to be highly over expressed when compared with samples of multinodular goiter (MNG) and normal controls. Interestingly, it was also noted that miRNA-221 and miRNA-222 expression is working in a cluster in thyroid cancer patients. So, it can be concluded that the expressional alterations of miRNA-221 and -222 are playing their potential role in the development of thyroid cancer.

Citing Articles

MicroRNA Profiling in Papillary Thyroid Cancer.

Armos R, Bojtor B, Papp M, Illyes I, Lengyel B, Szili B Int J Mol Sci. 2024; 25(17).

PMID: 39273308 PMC: 11395536. DOI: 10.3390/ijms25179362.

The impact of COVID-19 on microRNA and CD marker expression in AML patients.

Saeed R, Abdulrahman Z, Mohammad D Sci Rep. 2024; 14(1):14251.

PMID: 38902412 PMC: 11190249. DOI: 10.1038/s41598-024-64775-1.

Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.

Saeed R, Abdulrahman Z, Mohammad D Saudi J Biol Sci. 2024; 31(7):104027.

PMID: 38831894 PMC: 11145380. DOI: 10.1016/j.sjbs.2024.104027.

References

Chen X, Yan G . Novel human lncRNA-disease association inference based on lncRNA expression profiles. Bioinformatics. 2013; 29(20):2617-24. DOI: 10.1093/bioinformatics/btt426. View

Chou C, Chen R, Chou F, Chang H, Chen Y, Lee Y . miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 2010; 20(5):489-94. DOI: 10.1089/thy.2009.0027. View

Nikiforova M, Tseng G, Steward D, Diorio D, Nikiforov Y . MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008; 93(5):1600-8. PMC: 2386678. DOI: 10.1210/jc.2007-2696. View

Yoon S, Chun S, Han E, Choi J, Jang S, Koh S . Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol. 2011; 42(10):1391-400. DOI: 10.1016/j.humpath.2010.12.010. View

Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin G . MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008; 27(43):5651-61. DOI: 10.1038/onc.2008.178. View

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F . MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005; 102(50):18081-6. PMC: 1312381. DOI: 10.1073/pnas.0506216102. View

Heidari Z, Mohammadpour-Gharehbagh A, Eskandari M, Harati-Sadegh M, Salimi S . Genetic polymorphisms of miRNA let7a-2 and pri-mir-34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features. J Cell Biochem. 2018; 120(5):8640-8647. DOI: 10.1002/jcb.28152. View

Li X, Abdel-Mageed A, Mondal D, Kandil E . MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med. 2012; 6(1):74-80. PMC: 3515973. View

10.

Keutgen X, Filicori F, Crowley M, Wang Y, Scognamiglio T, Hoda R . A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res. 2012; 18(7):2032-8. DOI: 10.1158/1078-0432.CCR-11-2487. View

11.

Chou C, Yang K, Chou F, Huang C, Lan Y, Lee Y . Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012; 98(2):E196-205. DOI: 10.1210/jc.2012-2666. View

12.

Pallante P, Visone R, Croce C, Fusco A . Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer. 2009; 17(1):F91-104. DOI: 10.1677/ERC-09-0217. View

13.

Li G, He L, Huang J, Liu J, Chen W, Zhong J . miR-142-3p encapsulated in T lymphocyte-derived tissue small extracellular vesicles induces Treg function defect and thyrocyte destruction in Hashimoto's thyroiditis. BMC Med. 2023; 21(1):206. PMC: 10242775. DOI: 10.1186/s12916-023-02914-7. View

14.

Lee Y, Lim Y, Lee J, Wang S, Park H, Kim S . Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. Oral Oncol. 2014; 51(1):77-83. DOI: 10.1016/j.oraloncology.2014.10.006. View

15.

Kim H, Kim Y, Lee D, Chung J, Kim S . In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma. J Nucl Med. 2008; 49(10):1686-93. DOI: 10.2967/jnumed.108.052894. View

16.

Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V . MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14(3):791-8. DOI: 10.1677/ERC-07-0129. View

17.

Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

18.

Teixeira A, Dias F, Gomes M, Fernandes M, Medeiros R . Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?. J Kidney Cancer VHL. 2017; 1(8):84-98. PMC: 5345530. DOI: 10.15586/jkcvhl.2014.19. View

19.

Pallante P, Battista S, Pierantoni G, Fusco A . Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol. 2013; 10(2):88-101. DOI: 10.1038/nrendo.2013.223. View

20.

Suresh R, Sethi S, Ali S, Giorgadze T, Sarkar F . Differential Expression of MicroRNAs in Papillary Thyroid Carcinoma and Their Role in Racial Disparity. J Cancer Sci Ther. 2015; 7(5):145-154. PMC: 4570618. DOI: 10.4172/1948-5956.1000340. View